ABOUT (+)-JQ-1 MECHANISM OF ACTION

Semaglutide, a glucagon like peptide-one (GLP-one) receptor agonist, is offered as monotherapy in both subcutaneous together with oral dosage form (to start with authorized oral GLP-one receptor agonist). It's been authorised being a second line treatment option for much better glycaemic control in type two diabetes and at present below scrutiny fo